---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-004126"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:30:19.288014+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Genprex signs amended exclusive license with Univ of Pittsburgh for diabetes gene therapy, forms subsidiary

## Summary
- Entered amended and restated exclusive license with Univ of Pittsburgh for T1D and T2D gene therapy using Pdx1 and MafA genes.
- License includes milestone payments up to approximately $4,825,000 and low single-digit royalties on sales.
- Terminated prior license agreements, including the November 2022 macrophage technology license.
- Formed wholly-owned subsidiary Convergen Biotech, Inc. to focus on diabetes program development.
- Plans to request FDA guidance for IND-enabling diabetes studies by the second half of 2025.

## SEC filing metadata
- accession: 0001437749-25-004126
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925004126/0001437749-25-004126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925004126/gnpx20241220c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-004126
- JSON: https://secwatch.observer/filing/0001437749-25-004126.json
- Plain text: https://secwatch.observer/filing/0001437749-25-004126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.